Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/8587
Title: Gemcitabine/cisplatin treatment induces concomitant sertad1, cdkn2b and gadd45a modulation and cellular changes in bladder cancer cells regardless of the site of TP53 mutation.
Authors: Silva, Glenda Nicioli da
Filoni, Leandro Toshio
Salvadori, Maria Cecília Barbosa da Silveira
Salvadori, Daisy Maria Fávero
Keywords: Cell morphology
Chemotherapy
Gene expression
Issue Date: 2017
Citation: SILVA, G. N. et al. Gemcitabine/cisplatin treatment induces concomitant sertad1, cdkn2b and gadd45a modulation and cellular changes in bladder cancer cells regardless of the site of TP53 mutation. Pathology & Oncology Research, v. x, p. x-x, 2017. Disponível em: <https://link.springer.com/article/10.1007%2Fs12253-017-0255-x#copyrightInformation>. Acesso em: 29 ago. 2017.
Abstract: Simultaneous use of cisplatin (CIS) and gemcitabine (GEN) for treating bladder cancer has increased because of their complementary effects. However, the molecular mechanisms underlying the activities of these two antineoplastic drugs are not fully known. Here, molecular biology techniques and microscopy were used to investigate transcriptomic and morphological changes in low and highgrade urinary bladder transitional carcinoma cell lines [RT4 - wild type TP53; 5637 - two TP53 mutations, one in codon 72 (Arg-Pro) and other in codon 280 (Arg-Thr) and T24 - inframe deletion of tyrosine 126 in the TP53 allele] simultaneously treated with CIS/GEN. Gene expression profile was evaluated by PCR arrays; cell morphology by scanning and transmission electron microscopy, and apoptosis was analyzed using fluorescent dye. Results showed concomitantly upregulation of CDKN2B (G1/S transition), GADD45A (DNA repair and apoptosis) and SERTAD1 (regulation of transcription) gene, increased number of nuclear chamfers and apoptotic cells, and reduced number of microfilaments, organelles and in the size of the nucleus in 5637 and T24 cells after simultaneous treatment with CIS/GEN. In conclusion, independently of the TP53 mutation status and tumor grade, CIS/ GEN induced gene modulation accompanied by changes in cell morphologies, which confirm the antiproliferative activity of the treatment protocol. These findings help to understand the pathways modulated by these antineoplastic agents and may provide insights for anti-cancer chemotherapy.
URI: http://www.repositorio.ufop.br/handle/123456789/8587
metadata.dc.identifier.uri2: https://link.springer.com/article/10.1007%2Fs12253-017-0255-x#copyrightInformation
metadata.dc.identifier.doi: https://doi.org/10.1007/s12253-017-0255-x
ISSN: 1532-2807
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_GemcitabineCisplatinTreatment.pdf3,15 MBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.